Migard (Frovatriptan)

Frovatriptan, the active ingredient in Migard, is a Triptan (5‑HT1B/1D receptor agonist) presented as an oral tablet for oral use. It is indicated for the acute treatment of migraine attacks in adult patients. GNH USA supplies Migard as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Frovatriptan belongs to the Triptan class and is used for acute migraine management. - Migraine attacks: provides rapid relief of headache pain, nausea, photophobia and phonophobia. - Migraine with aura: reduces the severity of aura symptoms and associated headache when taken early. - Episodic migraine episodes: used as an as‑needed therapy to manage recurrent migraine attacks.

Frovatriptan may cause a range of adverse reactions, most of which are mild to moderate in severity.

Common Side Effects: - Nausea: mild to moderate feeling of stomach upset. - Dizziness: transient light‑headedness or vertigo. - Fatigue: feeling unusually tired after dosing. - Dry mouth: reduced salivation. - Chest discomfort: mild pressure or tightness. - Tingling sensations: paresthesia in extremities.

Serious or Rare Side Effects: - Coronary vasospasm: constriction of heart arteries that can cause chest pain. - Myocardial infarction: rare heart attack events. - Serotonin syndrome: potentially life‑threatening condition when combined with other serotonergic agents. - Severe hypertension: abrupt increase in blood pressure. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Cardiac arrhythmia: irregular heart rhythm.

Before prescribing Frovatriptan, clinicians should consider several safety aspects. - Assess cardiovascular history: evaluate for ischemic heart disease, uncontrolled hypertension or cerebrovascular disorders. - Review concomitant serotonergic drugs: avoid combined use that may precipitate serotonin syndrome. - Evaluate hepatic function: dose adjustment may be required in severe liver impairment. - Counsel on timing of dose: take at the first sign of migraine for optimal efficacy. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Frovatriptan can interact with several medication classes; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid): - MAO‑inhibitors: risk of severe hypertension and serotonin syndrome. - Other Triptans or ergot derivatives: additive vasoconstrictive effects. - SSRIs, SNRIs, or other serotonergic agents: heightened risk of serotonin syndrome.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase plasma levels of Frovatriptan. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - Antihypertensive agents: monitor blood pressure for additive effects.